[go: up one dir, main page]

NO20062672L - Interleukin-10-antistoffer - Google Patents

Interleukin-10-antistoffer

Info

Publication number
NO20062672L
NO20062672L NO20062672A NO20062672A NO20062672L NO 20062672 L NO20062672 L NO 20062672L NO 20062672 A NO20062672 A NO 20062672A NO 20062672 A NO20062672 A NO 20062672A NO 20062672 L NO20062672 L NO 20062672L
Authority
NO
Norway
Prior art keywords
antibodies
interleukin
methods
humanized
pathogen
Prior art date
Application number
NO20062672A
Other languages
English (en)
Inventor
Leonard G Presta
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20062672L publication Critical patent/NO20062672L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Fremgangsmåtene og preparatene som er tilveiebrakt her, vedrører generelt IL-10-spesifikke antistoffer og anvendelser derav, mer spesifikt, preparater av humaniserte IL-10-spesifikke antistoffer og fremgangsmåter for å anvende slike antistoffer ved modulering av den biologiske aktiviteten til IL-10, spesielt ved autoimmunforstyrrelser og patogenmediert immunpatologi.
NO20062672A 2003-11-10 2006-06-09 Interleukin-10-antistoffer NO20062672L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51899903P 2003-11-10 2003-11-10
PCT/US2004/037518 WO2005047326A2 (en) 2003-11-10 2004-11-09 Interleukin-10 antibodies

Publications (1)

Publication Number Publication Date
NO20062672L true NO20062672L (no) 2006-06-09

Family

ID=34590335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062672A NO20062672L (no) 2003-11-10 2006-06-09 Interleukin-10-antistoffer

Country Status (26)

Country Link
US (5) US20050101770A1 (no)
EP (4) EP2292661A3 (no)
JP (4) JP4762148B2 (no)
KR (3) KR20120025618A (no)
CN (2) CN102010471A (no)
AR (3) AR046833A1 (no)
AT (1) ATE440867T1 (no)
AU (2) AU2004290044B2 (no)
CA (2) CA2545255C (no)
CY (1) CY1110557T1 (no)
DE (1) DE602004022855D1 (no)
DK (1) DK1694705T3 (no)
ES (1) ES2329907T3 (no)
HK (1) HK1087722A1 (no)
HR (1) HRP20090517T1 (no)
IL (3) IL175523A (no)
NO (1) NO20062672L (no)
NZ (1) NZ546632A (no)
PE (3) PE20090046A1 (no)
PL (1) PL1694705T3 (no)
PT (1) PT1694705E (no)
RS (1) RS51180B (no)
SG (1) SG155205A1 (no)
SI (1) SI1694705T1 (no)
WO (2) WO2005047324A2 (no)
ZA (1) ZA200603681B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500247A (ja) * 2000-12-07 2005-01-06 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム ヒトｍｄａ−７に関わる処置方法
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
CA2548220A1 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
CN1913839B (zh) * 2004-02-23 2010-04-28 斯恩蒂斯有限公司 用于骨固定的装置
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
EP1863516A2 (en) * 2005-02-08 2007-12-12 Board of Regents, The University of Texas System Compositions and methods involving mda-7 for the treatment of cancer
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
WO2007027714A2 (en) 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
BRPI0716249A2 (pt) * 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
CN101605814B (zh) 2006-12-14 2014-02-19 默沙东公司 经工程改造的抗tslp抗体
CN101631773A (zh) 2006-12-22 2010-01-20 先灵公司 治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
KR20090106539A (ko) * 2006-12-22 2009-10-09 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
SG191442A1 (en) * 2006-12-22 2013-07-31 Schering Corp Us Antibodies to cd200r
CA2674831A1 (en) 2006-12-22 2008-11-13 Schering Corporation 5,6-ring annulated indole derivatives and methods of use thereof
EP2426144B1 (en) 2007-02-23 2018-10-31 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
MX2009009080A (es) 2007-02-23 2009-11-02 Schering Corp Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
AU2008219684B2 (en) 2007-02-28 2014-04-17 Merck Sharp & Dohme Corp. Engineered anti-IL-23R antibodies
PE20090630A1 (es) * 2007-08-29 2009-05-16 Schering Corp Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
KR20100065167A (ko) * 2007-08-29 2010-06-15 쉐링 코포레이션 바이러스 감염 치료용 2,3-치환된 아자인돌 유도체
US8143305B2 (en) * 2007-08-29 2012-03-27 Schering Corporation 2,3-substituted indole derivatives for treating viral infections
JP5249344B2 (ja) * 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション ヘテロ環の３位が置換されたインドール誘導体およびその使用
CN102317285A (zh) * 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
CN102159579B (zh) * 2008-06-13 2015-03-25 默沙东公司 三环吲哚衍生物及其使用方法
EP2331579B1 (en) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
BRPI1005984A2 (pt) * 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
KR101802261B1 (ko) * 2009-11-30 2017-11-28 바이오테스트 아게 전신 홍반성 낭창을 치료하기 위한 인간화된 항-ｉｌ-10 항체
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CN102918049A (zh) 2010-03-09 2013-02-06 默沙东公司 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法
NZ603581A (en) * 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US9254292B2 (en) 2010-09-29 2016-02-09 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012069433A2 (en) 2010-11-23 2012-05-31 Glaxo Group Limited Antigen binding proteins
EP3885366A3 (en) 2011-01-14 2021-12-29 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
SG194485A1 (en) 2011-04-13 2013-12-30 Merck Sharp & Dohme 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN102250243B (zh) * 2011-07-01 2013-08-28 华绍炳 抗白细胞介素-15抗体
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
US9512405B2 (en) 2011-12-14 2016-12-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Non-enzymatic method for isolating human adipose-derived stromal stem cells
KR102207859B1 (ko) 2013-03-15 2021-01-27 메모리얼 슬로안 케터링 캔서 센터 고 친화도 항-gd2 항체
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CN105277638A (zh) * 2014-07-22 2016-01-27 沈鹤霄 一种单克隆抗体IgG质谱测序方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN108025018B (zh) * 2015-05-29 2021-08-17 默沙东公司 用于治疗癌症的pd-1拮抗剂和cpg-c型寡核苷酸的组合产品
MA44700A (fr) * 2015-05-29 2019-02-27 Dynavax Tech Corp Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
KR102194188B1 (ko) 2015-11-18 2020-12-24 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｌａｇ３抗体および抗原結合性フラグメント
WO2017112621A1 (en) * 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CA3079076A1 (en) 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
WO2019179420A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
KR20230110304A (ko) 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
CN118043349B (zh) * 2021-06-11 2024-11-15 丰华生物有限公司 一种人源化抗人GPVI单克隆抗体Fab片段及其应用
WO2024091417A1 (en) * 2022-10-24 2024-05-02 Merck Sharp & Dohme Llc Human hyaluronidase 1 mutants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US6312680B1 (en) 1990-06-29 2001-11-06 Timothy R. Mosmann Methods of treatment using cytokine synthesis inhibitory factor
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
HU224437B1 (hu) * 1991-08-06 2005-09-28 Schering Corp. Eljárás interleukin-10 analógokat vagy antagonistákat tartalmazó endotoxin- vagy szuperantigén-indukált toxicitás kezelésére szolgáló gyógyszerkészítmények előállítására
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
AU680628B2 (en) * 1992-08-20 1997-08-07 Schering Corporation Novel uses of IL-4 and/or IL-10, and antibodies against the same
DE19529026C2 (de) * 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
WO2001054732A1 (en) * 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
CN1671416B (zh) * 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
US7148038B2 (en) * 2001-10-16 2006-12-12 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
ATE435239T1 (de) * 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen

Also Published As

Publication number Publication date
WO2005047326A2 (en) 2005-05-26
AU2004290044B2 (en) 2010-11-18
HRP20090517T1 (en) 2009-10-31
HK1087722A1 (en) 2006-10-20
PT1694705E (pt) 2009-11-30
AR074779A2 (es) 2011-02-09
KR101175055B1 (ko) 2012-08-22
US20070178097A1 (en) 2007-08-02
IL202681A0 (en) 2010-06-30
US7662379B2 (en) 2010-02-16
CY1110557T1 (el) 2015-04-29
US20140112919A1 (en) 2014-04-24
EP1694705A2 (en) 2006-08-30
NZ546632A (en) 2009-07-31
DK1694705T3 (da) 2009-12-07
ATE440867T1 (de) 2009-09-15
PL1694705T3 (pl) 2010-02-26
CA2545255C (en) 2013-06-25
EP2128175A1 (en) 2009-12-02
DE602004022855D1 (de) 2009-10-08
US20120282253A1 (en) 2012-11-08
JP2011087590A (ja) 2011-05-06
KR20120023858A (ko) 2012-03-13
EP2123678A1 (en) 2009-11-25
US8226947B2 (en) 2012-07-24
AU2004290044A1 (en) 2005-05-26
AU2011200606B2 (en) 2012-05-10
PE20050925A1 (es) 2005-11-29
SI1694705T1 (sl) 2010-01-29
CN100595212C (zh) 2010-03-24
IL202682A0 (en) 2010-06-30
IL202681A (en) 2011-10-31
AR046833A1 (es) 2005-12-28
JP2011062211A (ja) 2011-03-31
CN102010471A (zh) 2011-04-13
US8624013B2 (en) 2014-01-07
AU2011200606A1 (en) 2011-03-03
ZA200603681B (en) 2010-01-27
IL175523A (en) 2011-01-31
EP1694705B1 (en) 2009-08-26
PE20090046A1 (es) 2009-01-26
JP2008500020A (ja) 2008-01-10
AR074780A2 (es) 2011-02-09
US20050101770A1 (en) 2005-05-12
US20100203049A1 (en) 2010-08-12
CA2545255A1 (en) 2006-05-05
WO2005047326A3 (en) 2005-12-22
EP2292661A2 (en) 2011-03-09
WO2005047324A2 (en) 2005-05-26
CN1906213A (zh) 2007-01-31
JP4762148B2 (ja) 2011-08-31
ES2329907T3 (es) 2009-12-02
EP2292661A3 (en) 2011-06-22
JP2014014361A (ja) 2014-01-30
IL175523A0 (en) 2006-09-05
PE20090047A1 (es) 2009-01-26
CA2812856A1 (en) 2005-05-26
RS51180B (sr) 2010-10-31
KR20120025618A (ko) 2012-03-15
SG155205A1 (en) 2009-09-30
KR20060120093A (ko) 2006-11-24

Similar Documents

Publication Publication Date Title
NO20062672L (no) Interleukin-10-antistoffer
EP2345671B8 (en) Optimized fc variants and methods for their generation
EA200800812A1 (ru) Композиции антитела против cd3
EA201100128A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
WO2004099249A3 (en) Optimized fc variants and methods for their generation
MY163480A (en) Sclerostin binding agents
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
RS50858B (sr) Anti-tnf antitela, kompozicije, metode i njihove upotrebe
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
EP2270045B8 (en) Antibodies against Clostridium difficile toxins and uses thereof
NO20060236L (no) Antistoffer spesifikke for sklerostinro og fremgangsmate for a oke benmineralisering
RS28904A (en) Angiopoietin-2 specific binding agents
DK3085783T3 (da) Bispecifikt antistof som substitution for funktionelle proteiner
DK1483294T3 (da) Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse
NO20040752L (no) Humane antistoffer spesifikke for interleukin 15 (IL-15)
RS53318B (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2004007679A3 (en) Dendritic cell pontentiation
WO2004067568A3 (en) Human il-1 beta antagonists
NO20061412L (no) Terapi av okulaere foretyrrelser
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
WO2004113500A3 (en) B7s1: an immune modulator
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

FC2A Withdrawal, rejection or dismissal of laid open patent application